VectorBuilder has teamed up with Univercells Technologies to develop and optimise platform processes for the production of custom viral vectors for cell and gene therapies, as well as vaccine applications.
Rapid advances in cell and gene therapy in recent years, as well as the intense interest in recombinant viral vaccines brought on by COVID-19, have significantly increased the demand for custom viral vectors, especially GMP-grade vectors. The new partnership aims to utilise both companies’ capabilities, services and existing technologies to develop a portfolio of optimised viral vector manufacturing protocols to help maximise customers’ performance and commercial success.
“We are extremely pleased to be partnering with Univercells Technologies to co-develop optimised, scalable and customisable solutions for fast and affordable production of viral vectors. This partnership is an important step in VectorBuilder’s ambition to become a global leader in high performance, commercial-scale biomanufacturing,” said Dr Jason Ye, Vice President of Biomanufacturing at VectorBuilder.
“We are very excited to partner with VectorBuilder, a global pioneer in custom viral vector manufacturing,” added Mathias Garny, CEO of Univercells Technologies. “Our combined expertise and knowhow will help us to maximise the benefits of our manufacturing technologies, offering unparalleled solutions for integrated, continuous manufacture to our customers.”
Univercells Technologies’ scale-X bioreactors portfolio and the NevoLine Upstream platform offer high-performing production capacities while drastically reducing footprint and costs. The scale-X hydro (2.4 m2) and carbo (10 and 30 m2) bioreactors are suitable for accelerating process development and supporting clinical validation. They are complemented by the NevoLine Upstream platform – featuring an integrated scale-X nitro (200 and 600 m2) bioreactor. For more information, visit the VectorBuilder website.
